Benedetta Guidi

Dr. Benedetta Guidi

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
VCVincenzo Castiglione
Vincenzo Castiglione
MMMartina Modena
Martina Modena
AAAlberto Aimo
Alberto Aimo
ECEnrica Chiti
Enrica Chiti
NBNicoletta Botto
Nicoletta Botto
MEMichele Emdin
Michele Emdin
Molecular autopsy is the process of investigating sudden death through genetic analysis. It is particularly useful in cases where traditional autopsy is negative or only shows non-diagnostic features, i.e., in sudden unexplained deaths (SUDs), which are often due to an underlying inherited arrhythmogenic cardiac disease. The final goal of molecular autopsy in SUD cases is to aid medico-legal inquiries and to guide cascade genetic screening of the victim’s relatives. Early attempts of molecular autopsy relied on Sanger sequencing, which, despite being accurate and easy to use, has a low throughput and can only be employed to analyse a small panel of genes. Conversely, the recent adoption of next-generation sequencing (NGS) technologies has allowed exome/genome wide examination, providing an increase in detection of pathogenic variants and the discovery of newer genotype-phenotype associations. NGS has nonetheless brought new challenges to molecular autopsy, especially regarding the clinical interpretation of the large number of variants of unknown significance detected in each individual.

8 September 2021 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
BGBenedetta Guidi
Benedetta Guidi
APAndrea Parziale
Andrea Parziale
LNLuca Nocco
Luca Nocco
AMAniello Maiese
Aniello Maiese
RRRaffaele La Russa
Raffaele La Russa
ETEmanuela Turillazzi
Emanuela Turillazzi

4 May 2018 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
BGBenedetta Guidi
Benedetta Guidi
GAGiovanni Donato Aquaro
Giovanni Donato Aquaro
MGMarco Gesi
Marco Gesi
MEMichele Emdin
Michele Emdin
MPMarco Di Paolo
Marco Di Paolo

21 November 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
GAGiovanni Donato Aquaro
Giovanni Donato Aquaro
BGBenedetta Guidi
Benedetta Guidi
FBFederico Biondi
Federico Biondi
ECEnrica Chiti
Enrica Chiti
ASAlessandro Santurro
Alessandro Santurro
Di Paolo MarcoDi Paolo Marco
Di Paolo Marco
Background: Post-mortem cardiac magnetic resonance (PMCMR) is an emerging tool supporting forensic medicine for the identification of the causes of cardiac death, such as hypertrophic cardiomyopathy (HCM). We proposed a new method of PMCMR to diagnose HCM despite myocardial rigor mortis. Methods: We performed CMR in 49 HCM patients, 30 non-HCM hypertrophy, and 32 healthy controls. In cine images, rigor mortis was simulated by the analysis of the cardiac phase corresponding to 25% of diastole. Left ventricular mass, mean, and standard deviation (SD) of WT, maximal WT, minimal WT, and their difference were compared for the identification of HCM. These parameters were validated at PMCMR, evaluating eight hearts with HCM, 10 with coronary artery disease, and 10 with non-cardiac death. Results: The SD of WT with a cut-off of > 2.4 had the highest accuracy to identify HCM (AUC 0.95, 95% CI = 0.89–0.98). This was particularly evident in the female population of HCM (AUC=0.998), with 100% specificity (95% CI = 85–100%) and 96% sensitivity (95% CI = 79–99%). Using this parameter, at PMCMR, all of the eight patients with HCM were correctly identified with no false positives. Conclusions: PMCMR allows identification of HCM as the cause of sudden death using the SD of WT > 2.4 as the diagnostic parameter.

1 October 2015 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MEMichele Emdin
Michele Emdin
BGBenedetta Guidi
Benedetta Guidi
GVGiuseppe Vergaro
Giuseppe Vergaro
MEMichele Emdin
Michele Emdin

1 June 2017 in Romanian Journal of Legal Medicine
Verified
Journal Article
Closed access
MPMarco Di Paolo
Marco Di Paolo
Valentina BugelliValentina Bugelli
Valentina Bugelli
MFMichele Figus
Michele Figus
SFStefania Fornaro
Stefania Fornaro
BGBenedetta Guidi
Benedetta Guidi
MTMarco Tuccori
Marco Tuccori
A 60-year-old man, apparently healthy with negative history for cardiovascular diseases, was hospitalized because of an unilateral sudden and painless severe visual loss. Diagnosis of NAION was made. Two separate and immediately consecutive injections of betamethasone (2 mg/0.5 mL) and desmopressin (2 mcg/0.5 mL) were performed in the retrobulbar space. Fifteen minutes later, the patient suddenly developed cold sweat, dyspnoea, thoracic pain and severe hypotension. Acute myocardial infarction was diagnosed by ECG. Desmopressin was the probable causative agent. Thrombotic events following intravenous or oral administration of desmopressin have been documented in the medical literature. To the best of our knowledge this is the first case in which a thrombotic event was associated with the retrobulbar route. Retrobulbar desmopressin administration in patients with NAION can be probably associated with AMI. Considering its invasiveness and the unproven benefit in the treatment of NAION, this therapeutic approach can not be currently recommended.